ArticleOncotarget2015
Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Large-Scale Plasma Proteomics Reveals Preclinical Biomarkers of Incident Severe Liver Disease.Proteomics. Clinical applications · 2026Article
- Upregulation of spondin-2 indicates poorer clinical outcomes and induces radioresistance in gastric cancer.Translational cancer research · 2025Article
- Spon2 knockdown suppresses the phenotype of house dust mite-induced allergic asthma in mice and cells.Immunologic research · 2025Article
- Whole genome sequencing and single-cell transcriptomics identify KMT2D inactivation as a potential new driver for pituitary tumors: a case report.BJC reports · 2025Article
- Prognostic Value of Long Non-Coding RNAs GUSB Pseudogene 11 in Colorectal Cancer and Its Regulatory Effect on Tumor Progression.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Sperm DNA methylome abnormalities occur both pre- and post-treatment in men with Hodgkin disease and testicular cancer.Clinical epigenetics · 2023Article
- The biological functions and related signaling pathways of SPON2.Frontiers in oncology · 2023Review
- Tumor cell-derived SPON2 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by activating PYK2 in CRC.Journal of experimental & clinical cancer research : CR · 2021Article
- Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2.Abdominal radiology (New York) · 2021Article
- Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Increased Collagen Type V α2 (COL5A2) in Colorectal Cancer is Associated with Poor Prognosis and Tumor Progression.OncoTargets and therapy · 2021Article
- Mindin serves as a tumour suppressor gene during colon cancer progression through MAPK/ERK signalling pathway in mice.Journal of cellular and molecular medicine · 2020Article
- SPON2 Is Upregulated through Notch Signaling Pathway and Promotes Tumor Progression in Gastric Cancer.Cancers · 2020Article
- Article
- Upregulation of Spondin-2 protein expression correlates with poor prognosis in hepatocellular carcinoma.The Journal of international medical research · 2019Article
- The extracellular matrix protein mindin attenuates colon cancer progression by blocking angiogenesis via Egr-1-mediated regulation.Oncogene · 2018Article
- Bioinformatics Analysis Reveals Most Prominent Gene Candidates to Distinguish Colorectal Adenoma from Adenocarcinoma.BioMed research international · 2018Article
- Effect of long non-coding RNA Gas5 on proliferation, migration, invasion and apoptosis of colorectal cancer HT-29 cell line.Cancer cell international · 2018Article
- Cell Line Secretome and Tumor Tissue Proteome Markers for Early Detection of Colorectal Cancer: A Systematic Review.Cancers · 2017Review
- TumorOncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third and second most common cancer in males and females worldwide, respectively. Spondin-2 is a conserved secreted extracellular matrix protein and a candidate cancer biomarker. Here we found that Spondin-2 mRNA was upregulated in CRC tissues using quantitative RT-PCR and data-mining of public Oncomine microarray datasets. Spondin-2 protein was increased in CRC tissues, as revealed by immunohistochemistry analyses of two tissue microarrays containing 180 cases. Spondin-2 gene expression was significantly associated with CRC stage, T stage, M stage and Dukes stage, while its protein was associated with age and M stage. Kaplan-Meier analysis revealed that the upregulated Spondin-2 mRNA and protein predicted poor prognosis of CRC patients. Univariate and multivariate Cox regression analyses indicated that grade, recurrence, N stage and high Spondin-2 were independent predictors of overall survival of CRC patients. ELISA revealed that plasma Spondin-2 was upregulated in CRC and dropped after surgery. Receiver operating characteristic curve analysis demonstrated that plasma Spondin-2 has superior predictive performance for CRC with an area under the curve of 0.959 and the best sensitivity/specificity of 100%/90%. Furthermore, ectopic expression of Spondin-2 enhanced colon cancer cell proliferation. Spondin-2 could be an independent diagnostic and prognostic biomarker of colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.